<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00102869</url>
  </required_header>
  <id_info>
    <org_study_id>LL_001, Project on aphasia</org_study_id>
    <nct_id>NCT00102869</nct_id>
  </id_info>
  <brief_title>Dopaminergic Enhancement of Learning and Memory in Aphasia</brief_title>
  <official_title>Dopaminergic Enhancement of Learning and Memory (LL_001, Project on Aphasia)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Muenster</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Federal Ministry of Education and Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Muenster</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether levodopa, in combination with a high
      frequency language training, is effective in boosting naming performance in patients with
      aphasia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our prior work shows that d-amphetamine and the dopamine precursor levodopa markedly improve
      word learning success in healthy subjects. In this randomized, placebo-controlled,
      double-blind clinical trial, we probe whether daily administration of levodopa, coupled with
      several hours of language training every day, will significantly improve naming abilities in
      patients with aphasia as compared to placebo administration. We furthermore examine with
      magnetic resonance imaging which brain regions need to be functionally intact for a
      dopaminergic improvement of language therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Boost in naming performance (percent correct) through levodopa as compared to placebo</measure>
    <time_frame>immediately after each treatmentphase</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Brain activity pattern in successfully trained patients</measure>
    <time_frame>immediately after each treatmentphase</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stability of naming performance after one month and six months post treatment</measure>
    <time_frame>from 1 month untill 6 months after treatment completion</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">12</enrollment>
  <condition>Cerebrovascular Accident</condition>
  <condition>Aphasia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levodopa</intervention_name>
    <description>100mg levodopa per day over 10 days/ treatment phase</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for patients with aphasia:

          -  Unilateral cerebrovascular accident (stroke) in the territory of the arteria media

          -  Time post onset: &gt; 6 months

          -  Aphasia with anomia

          -  Age between 18-75 years

          -  Premorbid right-handedness

          -  Primary language: German

        Exclusion Criteria for patients and healthy controls:

          -  Known allergy to levodopa or tartrazine

          -  History of medication/drug abuse

          -  Acute nicotine withdrawal or &gt; 15 cigarettes per day

          -  &gt; 6 cups/glasses of coffee, caffeine drinks or energy drinks per day

          -  &gt; 50 grams of alcohol per day

          -  Severe hypertonia (systole &gt;180 mm Hg)

          -  Severe arteriosclerosis

          -  Diabetes, asthma, or glaucoma

          -  Severe hearing disability

          -  Evidence for severe hippocampal damage

          -  Premorbid depression or psychosis

          -  Medication with dopamine agonists or antagonists

          -  Parkinsonian symptoms

          -  Changes in anticonvulsive medication during the week prior to study enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Caterina Breitenstein, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Dept. of Neurology, University Hospital Muenster, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stefan Knecht, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Dept. of Neurology, University Hospital Muenster, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept. of Neurology, University Hospital Muenster</name>
      <address>
        <city>Muenster</city>
        <state>Nordrhein-Westfalen</state>
        <zip>48129</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://neurologie.uni-muenster.de/ger/mitarbeiter/breitenstein/</url>
    <description>Homepage of Dr. Breitenstein</description>
  </link>
  <reference>
    <citation>Knecht S, Breitenstein C, Bushuven S, Wailke S, Kamping S, Flöel A, Zwitserlood P, Ringelstein EB. Levodopa: faster and better word learning in normal humans. Ann Neurol. 2004 Jul;56(1):20-6.</citation>
    <PMID>15236398</PMID>
  </reference>
  <reference>
    <citation>Breitenstein C, Wailke S, Bushuven S, Kamping S, Zwitserlood P, Ringelstein EB, Knecht S. D-amphetamine boosts language learning independent of its cardiovascular and motor arousing effects. Neuropsychopharmacology. 2004 Sep;29(9):1704-14.</citation>
    <PMID>15114342</PMID>
  </reference>
  <reference>
    <citation>Breitenstein C, Knecht S. [Language acquisition and statistical learning]. Nervenarzt. 2003 Feb;74(2):133-43. Review. German.</citation>
    <PMID>12596014</PMID>
  </reference>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2005</study_first_submitted>
  <study_first_submitted_qc>February 3, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2005</study_first_posted>
  <last_update_submitted>October 4, 2013</last_update_submitted>
  <last_update_submitted_qc>October 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2013</last_update_posted>
  <responsible_party>
    <name_title>Rainer Girgenrath</name_title>
    <organization>Bundesministerium für Bildung und Forschung (BMBF)</organization>
  </responsible_party>
  <keyword>language acquisition</keyword>
  <keyword>plasticity</keyword>
  <keyword>stroke recovery</keyword>
  <keyword>aphasia treatment</keyword>
  <keyword>naming</keyword>
  <keyword>levodopa</keyword>
  <keyword>stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aphasia</mesh_term>
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Dopamine</mesh_term>
    <mesh_term>Dopamine Agents</mesh_term>
    <mesh_term>Dopamine Agonists</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>October 10, 2013</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>October 14, 2013</submitted>
    <returned>December 6, 2013</returned>
    <submitted>December 9, 2013</submitted>
    <returned>January 28, 2014</returned>
    <submitted>January 29, 2014</submitted>
    <returned>March 18, 2014</returned>
    <submitted>May 20, 2014</submitted>
    <returned>June 4, 2014</returned>
    <submitted>September 25, 2017</submitted>
    <returned>September 27, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

